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Outcome for Hong Kong residents
undergoing cadaveric liver
transplantation in mainland China
Objective. To review the outcome for Hong Kong residents undergoing cadaveric
liver transplantation in mainland China.
Design. Retrospective study.
Setting. Liver Transplant Centre, university teaching hospital, Hong Kong.
Subjects and methods. A retrospective review of medical records was under-
taken for patients at Queen Mary Hospital who underwent cadaveric liver trans-
plantation in China between 1 January 1997 and 31 December 2001.
Results. Fifteen patients from Queen Mary Hospital underwent cadaveric liver
transplantation in China during the study period. Eleven were men and four were
women. Their mean age was 51 years. Disease indications included hepatitis
B–related liver cirrhosis (n=7), hepatitis B–related liver cirrhosis with hepato-
cellular carcinoma (n=5), hepatitis C–related liver cirrhosis (n=1), hepatitis
C–related liver cirrhosis with hepatocellular carcinoma (n=1), and polycystic
liver and kidney disease (n=1). Nine patients were already waiting for liver trans-
plantation at Queen Mary Hospital, and two of the nine patients were on the
‘urgent’ list. The overall survival rate was 80.0% at 6 months and 73.3% at 12
months. There were four (27%) deaths, two of which occurred in China. Of the
11 surviving patients, nine (82%) developed complications. Nineteen complica-
tions were seen in the 13 patients who were managed in Hong Kong following
their return from China. Infective and biliary complications accounted for 58%
and 26% of complications, respectively. Major complications necessitated
prolonged hospitalisation for four patients and two required further laparotomy.
Conclusion. Although cadaveric liver transplantation in China is an option for
Hong Kong residents, patients and clinicians should be aware of the possible
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Introduction
Liver transplantation is the most effective treatment for end-stage liver diseases
and selected primary hepatic malignancies. Due to the prevalence of hepatitis B
Wong et al
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and Chinese religious and cultural traditions, however, the
availability of cadaveric donor organs is seriously restricted,
thus limiting its wide application in Hong Kong and other
Asian countries. At Queen Mary Hospital (QMH), the
average waiting time for a cadaveric graft is between 18
and 24 months. For those patients who are on the ‘urgent’
waiting list, only 10% receive a cadaveric liver transplant
within 7 days of listing.1 There is significant mortality dur-
ing the waiting period. Living donor liver transplantation
has been developed to relieve the organ shortage, both for
elective and urgent cases.2 With the use of living donors as
an alternate source of organs, the number of liver trans-
plantations at QMH has significantly increased in recent
years. Living donor liver transplantation accounts for more
than 70% of liver transplants to date. More than 50% of
transplant candidates do not have a living donor, however.3
The number of cadaveric liver transplantations undertaken
in mainland China has been increasing in recent years,4-6
and this treatment is also available to patients from Hong
Kong, with a much shorter waiting time but at a cost. Thus,
the option of going to China for cadaveric liver transplant-
ation has become attractive for a number of patients.
Despite the cost of the operation, the main concern with
this choice is the uncertainty regarding the results. The pur-
pose of this study was to evaluate the operative outcome for
patients from Hong Kong who undergo cadaveric liver trans-
plantation in mainland China.
Subjects and methods
The hospital records of 15 QMH patients who had liver trans-
plantation in hospitals in China between 1 January 1997 and
31 December 2001 were retrospectively reviewed. Nine
(60%) of the 15 patients were waiting for liver transplant-
ation at QMH before receiving liver transplantation in China.
During the same period, 144 adult liver transplants were per-
formed at QMH using 63 cadaveric and 81 living donor grafts.
Of the nine patients who had been waiting at QMH, eight
were men and one was a woman, with a mean age of 52
years (range, 41-65 years). All patients were evaluated and
accepted for liver transplantation according to a standard
protocol. The indications for liver transplantation were hepa-
titis B–related liver cirrhosis (n=4), hepatitis B–related liver
cirrhosis with hepatocellular carcinoma (n=3), and acute-
on-chronic hepatitis B (n=2). Two patients had been in the
Intensive Care Unit and on the ‘urgent’ waiting list at QMH
prior to travelling to China for transplantation. The duration
from joining the waiting list at QMH to transplantation in
China ranged from 2 weeks to 6 months (median, 1 month).
The two patients on the ‘urgent’ waiting list had family
members who had volunteered to be living donors but both
were considered unsuitable—one was considered psycho-
logically unfit, and the other was a chronic carrier of the
hepatitis B surface antigen. All nine patients who went to
China for liver transplantation did so on a voluntary basis.
It is hospital policy not to refer patients to China for consid-
eration of liver transplantation.
Of the six patients who were not waiting for liver trans-
plantation at QMH, three were men and three were women.
The mean age was 51 years (range, 41-63 years). Two
patients had hepatitis B–related liver cirrhosis with hepato-
cellular carcinoma, one had hepatitis C–related liver cirrhosis
with hepatocellular carcinoma, one had hepatitis B–related
liver cirrhosis, one had hepatitis C–related liver cirrhosis,
and one had polycystic disease of the liver and kidneys.
Five of the six patients had been evaluated but were not
accepted for future liver transplantation at QMH due to
contra-indications (three patients had advanced hepato-
cellular carcinoma), lack of an appropriate indication (one
patient with polycystic disease), and patient refusal (one
patient with hepatitis C–related liver cirrhosis). The remain-
ing patient with hepatitis B–related liver cirrhosis had not
been seen at QMH before undergoing liver transplantation
in China.
All patients were admitted to QMH when they returned
to Hong Kong after cadaveric liver transplantation in China,
and available information provided by the hospitals in China
was reviewed. Full assessments were performed, including
history, physical examination, blood tests (complete blood
count, clotting profile, liver and renal function tests, blood
glucose level, hepatitis status, and blood level of immuno-
suppressants), chest X-ray, and cholangiography if a T-tube
was in situ. The type and dosage of immunosuppressants were
reviewed and adjusted according to the current immuno-
suppression protocol, consisting of a double regimen of a
steroid and tacrolimus. The steroid was rapidly tapered off
with the aim of tacrolimus monotherapy 6 months after
transplantation. Lamivudine 100 mg daily prophylaxis was
used to prevent recurrent hepatitis B.
Results
The details of patient demographics, disease indications,
relevant dates (including time on the waiting list and date of
transplantation), duration of follow-up, mortality and
morbidity, and current status are reported in Tables 1 and 2.
The mean duration of follow-up was 9 months (range,
<1 month to 21 months). The survival rates were 80.0% at 6
months and 73.3% at 12 months. Two (13.3%) patients
(patients 1 and 2) who were on the list for urgent transplant-
ation died soon after transplantation during hospital stay in
China. The cause of death was unknown. One patient (patient
10) who had hepatitis C–related liver cirrhosis and hepato-
cellular carcinoma developed recurrent disease with bi-
lateral pulmonary metastases and died in Hong Kong 8
months after liver transplantation. Another patient (patient
3) who had hepatitis B–related liver cirrhosis and hepato-
cellular carcinoma had re-activation of hepatitis B and died
of liver failure and sepsis 4 months after transplantation.
The hospital stay at QMH for the 13 patients who
returned from mainland China ranged from 4 to 103
days (mean, 41.6 days; median, 24 days). Four patients
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developed major complications that necessitated prolonged
hospital stay (patients 5, 9, 10, and 12), and two required
repeat laparotomy. Patient 9, who had hepatitis B cirrhosis
with hepatocellular carcinoma, developed methicillin-
resistant Staphylococcus aureus and enterococcus peritonitis
2 weeks after transplantation, and laparotomy and peri-
toneal lavage were performed in China. The patient was
subsequently transferred to Hong Kong approximately 6
weeks after transplantation, and had a further complication
of a ruptured hepatic artery pseudoaneurysm. Laparotomy
was performed, which showed multiple intra-abdominal
abscesses eroding the hepatic artery and duodenum, leading
to duodenal perforation and bile leakage. This patient also
developed nosocomial pneumonia after surgery, requiring
temporary tracheostomy and mechanical ventilation, with
28 days respiratory support in the Intensive Care Unit. Pa-
tient 12, who had hepatitis B cirrhosis with hepatocellular
carcinoma, developed massive gastrointestinal bleeding from
liver and paracolic abscesses caused by aspergillus. These
necessitated laparotomy, colectomy, ileostomy, and drain-
age of the abscesses. Patient 5, who had hepatitis B–related
liver cirrhosis, developed diffuse ischaemic biliary stricture
and biloma formation after transplantation, which required
percutaneous transhepatic biliary drainage (PTBD) [Fig].
The patient was repeatedly admitted to QMH due to PTBD
blockage requiring flushing and revision under radiological
guidance. The patient is currently waiting for repeat trans-
plantation. Patient 10, who had hepatitis C cirrhosis with
hepatocellular carcinoma, developed methicillin-resistant S
Table 2. Morbidity in 15 Hong Kong residents following
cadaveric liver transplantation in mainland China
Type of morbidity No. of patients
Diffuse biliary stricture 3
Biliary leakage 2
Ruptured hepatic artery pseudoaneurysm 1
Segmental portal vein thrombosis 1
Duodenal perforation 1
Recurrent hepatitis B 3
De novo hepatitis B 1
De novo hepatitis C 2
Nosocomial pneumonia 2
Intra-abdominal abscess 1
Aspergillus paracolic abscess with 1
 enterocutaneous fistula
Yeast abscess of the palm 1
Table 1. Summary patient data for 15 Hong Kong residents who underwent cadaveric liver transplantation in mainland China
Patient Sex/age Disease Date of initial Date of Hospital Duration of Current patient
No. (years) indication placement cadaveric liver stay in follow-up status
on the waiting transplantation Hong Kong (months)
list at Queen in China (days)
Mary Hospital
1 M/51 Hepatitis B cirrhosis with Mar 99 Apr 99 - <1 Died (in hospital,
acute decompensation China)
2 M/41 Hepatitis B cirrhosis with Mar 99 Apr 99 - <1 Died (in hospital,
acute decompensation China)
3 M/63 Hepatitis B cirrhosis, Sep 00 Sep 00 4 4 Died (recurrent
hepatocellular carcinoma hepatitis B)
4 F/53 Hepatitis B cirrhosis, Jun 00 Dec 00 13 12 Alive
hepatocellular carcinoma
5 M/65 Hepatitis B cirrhosis Jan 01 Feb 01 103 11 Alive, pending
re-transplantation
6 M/47 Hepatitis B cirrhosis Apr 01 Jun 01 27 8 Alive
7 M/44 Hepatitis B cirrhosis Nov 00 Aug 01 17 8 Alive
8 M/46 Hepatitis B cirrhosis Jul 01 Sep 01 18 5 Alive
9 M/54 Hepatitis B cirrhosis, Sep 01 Oct 01 103 3 Alive
hepatocellular carcinoma
10 F/57 Hepatitis C cirrhosis, Not applicable Jun 98 96 8 Died (recurrent
hepatocellular carcinoma hepatocellular
carcinoma)
11 F/47 Polycystic disease of the Not applicable Jun 00 (combined 11 19 Alive
liver and kidneys liver and kidney)
12 M/49 Hepatitis B cirrhosis, Not applicable Sep 00 72 18 Alive
hepatocellular carcinoma
13 M/41 Hepatitis B cirrhosis, Not applicable Mar 01 24 9 Alive
hepatocellular carcinoma
14 F/63 Hepatitis C cirrhosis Not applicable Sep 01 23 5 Alive
15 M/43 Hepatitis B cirrhosis Not applicable Apr 00 30 21 Alive
Fig. Percutaneous transhepatic cholangiogram of patient 5
shows features of diffuse ischaemic biliary stricture (arrows)
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aureus pneumonia requiring mechanical ventilation. This
patient subsequently developed recurrent hepatocellular
carcinoma with persistent left pleural effusion and a right
lung hilar mass, and died 8 months after transplantation.
Of the 11 patients alive 3 to 21 months after liver trans-
plantation, nine (82%) developed complications. There
were 19 complications among 13 patients who returned to
Hong Kong. Two of these patients died from complications
(patients 3 and 10). Infective complications accounted for
58%, and the remaining 42% were surgical complications.
For infective complications, 55% were viral, 27% were
bacterial, and 18% were fungal. Patient 11, who had poly-
cystic disease and was hepatitis B surface antigen–negative
before transplantation, had de novo hepatitis B after trans-
plantation. Patient 15, who had hepatitis B cirrhosis,
developed recurrent hepatitis B as well as de novo hepatitis
C after cadaveric liver transplantation. There were two cases
of nosocomial pneumonia requiring mechanical ventilation
(patients 9 and 10), and one instance of intra-abdominal,
pyogenic abscess requiring laparotomy for drainage (pa-
tient 9). Patient 12, who had aspergillus liver and paracolic
abscesses, developed adhesions and an enterocutaneous
fistula after initial laparotomy. This patient subsequently
underwent two further operations. Patient 5 developed an
invasive yeast infection over the palm, requiring surgical
excision and a 9-month course of oral fluconazole. This
patient can only undergo re-transplantation once the fungal
infection is completely eradicated. Of the surgical compli-
cations, biliary causes accounted for 63%, while 37% were
vascular complications. Three patients had ischaemic bile
duct strictures. This was defined as a non-anastomotic intra-
hepatic biliary lesion with either two or more sites of stricture
formation and/or biliary dilatation, or multiple intrahepatic
fluid collections or abscesses.7 Hepatic artery patency was
confirmed by percutaneous Doppler ultrasound. Biliary leak-
age was demonstrated on T-tube cholangiography. Hepatic
artery pseudoaneurysm with rupture was diagnosed during
laparotomy for patient 9, who had intra-abdominal pyogenic
abscess. Segmental portal vein thrombosis was demonstrated
on computed tomographic scan of the liver and confirmed
with liver biopsy for patient 4.
Discussion
Although liver transplantation is the most effective treat-
ment for end-stage liver diseases, it is a highly sophisticated
procedure, and is associated with significant morbidity and
mortality. Complications that occur after liver transplant-
ation also have a significant impact on resource utilisation
and costs.8
This study has reported the outcome for 15 patients who
received cadaveric liver transplantation in mainland China.
There were two hospital deaths, and a further two patients
died 4 and 10 months after transplantation. The patient
survival rate was 80% at 6 months and 73.3% at 12 months,
while 82% had complications. Patients electing to travel to
mainland China for liver transplantation may represent a
selected group of high-risk patients. Two of the patients were
urgent candidates for liver transplantation and required
intensive care before they were transferred to China for
liver transplantation. Hence, it is not appropriate to view
the outcomes for these 15 patients as representative of the
results achieved with liver transplantation in China overall.
Unfortunately, publications in China are not well-indexed
in the international literature and, until recently, few papers
concerning liver transplantation in China had been pub-
lished.4-6 It is therefore difficult to access data on a large
case series of liver transplantation as a comparative standard.
Advanced hepatocellular carcinoma is a contra-
indication for liver transplantation because of the high risk
of recurrence. For selected patients with a small hepato-
cellular carcinoma that is not resectable because of location
or underlying cirrhosis, a 5-year survival rate of approxi-
mately 70% can be achieved after liver transplantation,
however. At QMH, liver transplantation for hepatocellular
carcinoma is restricted to patients with no more than three
tumour nodules of 5 cm or less, in the absence of macro-
scopic vascular permeation.9-11 The two patients (patients
10 and 12) with hepatocellular carcinoma and liver cirrho-
sis were not selected for liver transplantation due to the large
size of the primary tumour. For benign liver disease, liver
transplantation is considered at QMH only if the disease
has progressed to its terminal stage and there is no alter-
native treatment available. The patient with polycystic dis-
ease of the liver and kidney was not listed for transplantation,
as the liver and renal function were satisfactory, and she
was not debilitated by the hepatomegaly. These patients
highlight differences in selection criteria for transplantation
between QMH and hospitals in China.
After transplantation in mainland China, the recipients
returned to Hong Kong for follow-up care. The information
accompanying them was not always comprehensive. Infor-
mation regarding the status of the donor and the pathology
of the explanted liver, which are crucial for subsequent
management and follow-up, and for indicating possible
complications, were often missing. This added to difficult-
ies in the clinical management of this group of patients.
In this series, infection accounted for 58% of all
complications. Most infections occurring in the first month
were bacterial or fungal and were related to the surgical
procedure. These included intra-abdominal infections,
cholangitis, pneumonia, urinary tract infection, wound
infection, and catheter-related sepsis. Both recurrent and
de novo hepatitis were common in this group of patients.
Recurrence of hepatitis B virus is associated with reduced
patient and graft survival rates. The major risk factor for
graft hepatitis B infection is pre-transplantation of hepatitis
B, with the risk of recurrence greatest in patients whose
hepatitis B–DNA was positive at the time of transplant-
ation.12 Current strategies for prophylaxis against graft
hepatitis B include using hepatitis B immunoglobulin to
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bind and clear hepatitis B surface antigen–positive viral
particles,13 and using nucleoside analogues to inhibit hepa-
titis B viral replication. Lamivudine monotherapy is highly
effective for preventing recurrent hepatitis B.14
With regard to the two patients who developed de
novo hepatitis B and C, we suspect that the donor liver
grafts might have carried the virus, or that the patients were
given excess immunosuppressive therapy in the early post-
operative period. The assessment of the cadaveric liver graft
preoperatively is of the utmost importance to ensure trans-
mission of hepatitis does not occur. Transmission of hepa-
titis through the transfusion of blood products is a further
possibility in the absence of rigorous blood screening.
Surgical complications accounted for 42% of the remain-
ing complications, with biliary complications comprising
the majority. Biliary complications are a continuing con-
cern in liver transplantation, occurring in 8% to 15% of cases,
with a mortality rate of 10%.15 Diffuse biliary stricture—
occurring in three of the patients in this series (patients 5, 8,
and 13)—can be due to ischaemia from hepatic artery
thrombosis, extended graft preservation time and warm
ischaemic time, and ABO incompatibility and rejection.16 It
is likely that the occurrence of diffuse ischaemic bile duct
stricture in these cases was due to warm ischaemic injury to
the donor liver during harvesting, as all hepatic arteries in
these three patients were patent on Doppler ultrasound. In-
formation on the process of donor liver graft preservation,
and cold and warm ischaemic time during these patients’
procedures was not available. Diffuse ischaemic bile
duct stricture triggers the need for re-transplantation. Bile
leakage around the T-tube or after its removal is related to
inadequate development of the fibrous tract along the course
of the T-tube tract, probably caused by impairment of
fibrogenesis under steroid immunosuppression.17
Hepatic artery pseudoaneurysms are rare (0.2%-
0.9%) complications of liver transplantation. They usually
occur at sites of anastomosis and are often infected, causing
rupture and fatal haemorrhage, making early diagnosis
and treatment imperative.18 In the absence of infection,
resection and primary anastomosis or reconstruction with
an interposition graft can be performed. However, if there
is evidence of infection, as for patient 9, resection and ligat-
ion are mandatory even though re-transplantation may
ultimately be required.19
Patients from Hong Kong travel to mainland China for
liver transplantation to bypass the long waiting time for a
cadaveric graft and the lack of voluntary living liver donors
in Hong Kong. Despite the increase in cadaveric liver
donors as a result of public education and maximal use
of marginal donors during the past decade,3 the donor rate
has remained low overall at less than three per million popu-
lation per year. Although innovative techniques for living
donor liver transplantation have also expanded the donor
pool, more than 50% of transplant candidates do not have
a living donor.1 There are other measures to recruit more
donor livers but only limited success has been achieved to
date. Regional sharing of organs20 has a limited role in Asia
as most transplant centres are short of organs and do not
have any surplus for sharing. Although split-liver transplant-
ation offers an attractive concept of transplanting two pa-
tients with one donor liver,21 the logistical difficulties of
mounting two simultaneous transplants and the associated
resource constraints seriously limit its wide application in
Hong Kong at this time.
A substantial amount of hospital resources and man-
power were utilised in the treatment of Hong Kong resi-
dents who returned from China after cadaveric liver
transplantation seeking management of complications and
subsequent follow-up. It is inappropriate to make general-
isations based only on the outcome for the 15 patients
reviewed. Patients who decide to seek treatment in China
should be aware of the potential risks they may encounter,
however. Clinicians considering referral of patients to China
for consideration of cadaveric liver transplantation should
also be aware of the potential risks, as well as the resource
implications of appropriate patient follow-up on their
return to Hong Kong.
Conclusion
Liver transplantation is a complex procedure, with signifi-
cant morbidity and mortality. The scarcity of cadaveric liver
grafts in Hong Kong currently limits its wide application.
Cadaveric liver transplantation in mainland China is an
option for some patients, affording a shorter waiting time
for treatment. This review suggests the outcome may not
be favourable for a variety of reasons, including patient
status prior to surgery. Furthermore, it should be noted
that patients may utilise substantial hospital resources and
manpower on returning to Hong Kong for further manage-
ment of complications.
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